Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...

The lack of cost-effective methods for producing antimicrobial peptides has made it impossible to use their high potential as a new and powerful class of antimicrobial agents. In recent years, ...

The Maurolipin-pET-28a plasmid was extracted from E. coli DH5α cells grown in 20 mL Luria-Bertani (LB) medium supplemented with 50 μg/ml kanamycin, using the GeneAll ® plasmid extraction kit, and then ...

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...

In September 1970, Janet Mertz joined the biochemistry department at Stanford University. She was one of only six new graduate students in the department and the first female one admitted in nine ...

Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic ...

Forbes contributors publish independent expert analyses and insights. Scott Hutcheson teaches leadership at Purdue University. Faced with a crowded dining room and dwindling supplies, Cardini ...

Recombinant antibodies (rAbs), also called genetically engineered antibodies, are produced by cloning the antibody which is made of light and heavy chain DNA sequences. In comparison to monoclonal ...

insights from industryAmy ShengHead of CROSino Biological In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO program at Sino Biological US Inc., about current developments in the ...

The clinical diagnostic industry is on the verge of a recombinant protein revolution. Recombinants have been available for decades and have served some sectors of diagnostics quite well, but they have ...

Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. This ...